-
Mashup Score: 10Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer - 6 day(s) ago
Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to an approved precision oncology therapy.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer - 9 day(s) ago
Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to an approved precision oncology therapy.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Transplant Eligible and Ineligible Elderly Patients with AMLāA Genomic Approach and Next Generation Questions - 11 day(s) ago
The management of elderly patients diagnosed with acute myelogenous leukemia (AML) is complicated by high relapse risk and comorbidities that often preclude access to allogeneic hematopoietic cellular transplantation (allo-HCT). In recent years, fast-paced FDA drug approval has reshaped the therapeutic landscape, with modest, albeit promising improvement in survival. Still, AML outcomes in elderly patients remain unacceptably unfavorable highlighting the need for better understanding of disease biology and tailored strategies. In this review, we discuss recent modifications suggested by European Leukemia Network 2022 (ELN-2022) risk stratification and review recent aging cell biology advances with the discussion of four AML cases. While an older age, >60 years, does not constitute an absolute contraindication for allo-HCT, the careful patient selection based on a detailed and multidisciplinary risk stratification cannot be overemphasized.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
Approximately 8-10% of pancreatic ductal adenocarcinoma cases are KRAS wild-type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies - 1 month(s) ago
PURPOSE Human epidermal growth factor receptor 2 (HER2) expression (protein immunohistochemistry [IHC] or gene amplification [copy-number variation, CNV]) predicts anti-HER2 therapy responsiveness, although recently it was shown that even low HER2-expressing breast cancers benefit from trastuzumab-deruxtecan. Little is known about HER2 transcriptomic (mRNA) expression, and comparisons between genomic, mRNA, and protein HER2 assays. METHODS HER2 status was evaluated using clinical-grade IHC (protein), quantitative reverse transcription polymerase chain reaction (mRNA), and next-generation sequencing (NGS; amplifications). RESULTS Multi-institutional HER2 testing was performed on 5,305 diverse cancers including nonāsmall-cell lung (n = 1,175), breast (n = 1,040), and colon cancers (n = 566; N = 3,926 tested for CNV; N = 1,848, mRNA; N = 2,533, IHC). Overall, 4.1% (161/3,926) had NGS HER2 amplification; 33.3% (615/1,848) had mRNA overexpression; and 9.3% (236/2,533) were IHC-positive. In
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 67FDA approves an HDAC inhibitor for Duchenne muscular dystrophy - 1 month(s) ago
Nature Reviews Drug Discovery – Discover the worldās best science and medicine | Nature.com
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71Cancer Care in the Era of AI - 1 month(s) ago
This JAMA Oncology Patient Page explains artifical intelligence and what patients should know about how it can be used in oncology.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 105
Historically, cancer has been classified and treated on the basis of its organ of origin (e.g., breast or colon or lung cancer), which is determined by light microscopy. However, light microscopy does not uncover the factors that drive tumor formation and progression. Understanding tumor drivers requires molecular technology, which has fortunately advanced at a remarkable rate over the last two decades. As a result, there are now multiple tissue-agnostic Food and Drug Administration (FDA) approvals for patients with cancer (Fig.
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
AbstractPurpose:. Increased glucocorticoid receptor (GR) signaling is a proposed compensatory mechanism of resistance to androgen receptor (AR) inhibition in metastatic castration-resistant prostate cancer (mCRPC). ORIC-101 is a potent and selective orally-bioavailable GR antagonist.Patients and Methods:. Safety, pharmacokinetic/pharmacodynamic, and antitumor activity of ORIC-101 in combination with enzalutamide were studied in patients with mCRPC progressing on enzalutamide. ORIC-101 doses ranging from 80 to 240 mg once daily were tested in combination with enzalutamide 160 mg once daily. Pharmacokinetics/pharmacodynamics was assessed after a single dose and at steady state. Disease control rate (DCR) at 12 weeks was evaluated at the recommended phase 2 dose (RP2D).Results:. A total of 41 patients were enrolled. There were no dose-limiting toxicities and the RP2D was selected as 240 mg of ORIC-101 and 160 mg of enzalutamide daily. At the RP2D, the most common treatment-related adverse
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2About Workshop | vailworkshop.org - 2 month(s) ago
An intensive workshop in the essentials of effective clinical trial designs of therapeutic interventions in the treatment of cancer for clinical fellow and junior faculty clinical researchers in all oncology subspecialties, including radiation and surgical oncology and radiology. Affectionately known as the āVailā Workshop due to its history in Vail, CO, the 2024 Workshop will be in a new location! The 2024 Workshop will be held in sunny La Jolla, California. The new location represents a less travel
Source: vailworkshop.orgCategories: General Medicine News, Hem/OncsTweet
RT @ArndtVogel: Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer @CD_AACR https://t.co/VrqWI9NviL š4ā¦